Med-Pharmex Incorporated

Med-Pharmex Incorporated specializes in developing and distributing veterinary pharmaceutical products, enhancing the health of livestock and companion animals through effective treatments and preventative solutions. Founded in 1983, Med-Pharmex Incorporated operates primarily in Pomona, US, focusing on the veterinary market. The company has executed two notable deals, with the most recent being a Trade Sale in August 2022, where it was acquired by Dechra Pharmaceuticals PLC for GBP 221. 5 million, allowing for further expansion and scaling of their business.

Med-Pharmex, Inc. specializes in the development and distribution of pharmaceutical products for the veterinary market, focusing on the health and productivity of livestock and companion animals. Their key offerings include Ivermectin, marketed under the brand name Stromectol, available in 3mg and 12mg formulations. These products are designed to prevent and treat various parasitic and infectious diseases in domestic animals such as cattle, swine, and poultry, as well as to ensure optimal health in companion animals.

The company partners with major veterinary distributors across the United States, facilitating comprehensive national distribution. Internationally, Med-Pharmex has established a presence in several countries, catering to a diverse client base that includes veterinarians, farm operators, and pet owners, all of whom rely on these products to maintain animal health and productivity. Med-Pharmex generates revenue through a structured model that includes partnerships with veterinary distributors, enabling widespread access to its products. Transactions typically occur through wholesale agreements where distributors purchase pharmaceutical products in bulk to supply veterinary clinics and farms.

Individual products, such as Ivermectin, are offered at competitive prices, catering to a wide range of animal health needs. The company’s revenue model emphasizes B2B relationships, with distributors acting as intermediaries between Med-Pharmex and end users, including veterinarians and animal owners. The pricing structure is designed to appeal to a broad market, ensuring that products are accessible while supporting the company's growth and sustainability. Following the acquisition by Dechra Pharmaceuticals in August 2022, Med-Pharmex plans to leverage the funding to further expand its product offerings and distribution channels.

The company aims to introduce new veterinary pharmaceutical products in the coming years and explore expansion into additional international markets, increasing its global footprint. The recent capital infusion from the acquisition will support these strategic initiatives, allowing Med-Pharmex to scale its operations effectively.